PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Vaxcyte, Inc. (NASDAQ:PCVX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held Vaxcyte, Inc. (NASDAQ:PCVX) at the end of the first ...

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company that focuses on developing novel protein vaccines to prevent or treat bacterial infectious diseases.

Vaxcyte, Inc. (NASDAQ: PCVX) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Vaxcyte, Inc.

Fintel reports that on December 20, 2024, Goldman Sachs initiated coverage of Vaxcyte (NasdaqGS:PCVX) with a Buy recommendation. Analyst Price Forecast Suggests 79.54% Upside As of December 3 ...

Vaxcyte, Inc. (NASDAQ:PCVX) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 48 hedge fund portfolios held Vaxcyte, Inc. (NASDAQ:PCVX) at the end of the third ...

Vaxcyte (NASDAQ:PCVX) just reported results for the first quarter of 2024. Vaxcyte reported earnings per share of -85 cents. This was above the analyst estimate for EPS of -$1.09. The company did ...